Disruption of the hexokinase-VDAC complex for tumor therapy.
about
Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosisReviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer TherapyIntracellular ion channels and cancerThe crystal structure of mouse VDAC1 at 2.3 A resolution reveals mechanistic insights into metabolite gatingMethyl jasmonate: putative mechanisms of action on cancer cells cycle, metabolism, and apoptosisAcidification asymmetrically affects voltage-dependent anion channel implicating the involvement of salt bridges.Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer.Subcellular localization of hexokinases I and II directs the metabolic fate of glucose.Mitochondrial VDAC1: A Key Gatekeeper as Potential Therapeutic TargetPerillyl alcohol and methyl jasmonate sensitize cancer cells to cisplatinPotential therapeutic benefits of strategies directed to mitochondria.Mitochondrial approaches to protect against cardiac ischemia and reperfusion injury.Targeting the actin cytoskeleton: selective antitumor action via trapping PKCɛThe mitochondrial death pathway: a promising therapeutic target in diseasesEmerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy.Metabolic Plasticity in Cancer Cells: Reconnecting Mitochondrial Function to Cancer Control.Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cellsProapoptotic Role of Potassium Ions in Liver CellsMitochondria-mediated energy adaption in cancer: the H(+)-ATP synthase-geared switch of metabolism in human tumors.Myostatin induces mitochondrial metabolic alteration and typical apoptosis in cancer cellsThe electrostatics of VDAC: implications for selectivity and gating.Hexokinase-mitochondrial interactions regulate glucose metabolism differentially in adult and neonatal cardiac myocytes.Light activation of the insulin receptor regulates mitochondrial hexokinase. A possible mechanism of retinal neuroprotectionAspirin induces cell death by directly modulating mitochondrial voltage-dependent anion channel (VDAC).Targeting malignant mitochondria with therapeutic peptides.The anti-cancer activities of jasmonates.Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy.Mitochondrial channels: ion fluxes and more.Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition.Hexokinases and cardioprotection.Crosstalk between calcium and reactive oxygen species signaling in cancer.Mitochondrial VDAC and hexokinase together modulate plant programmed cell death.PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials.Two-color STED microscopy reveals different degrees of colocalization between hexokinase-I and the three human VDAC isoforms.Metabolic control of the cell cycle.Mitochondrial SSBP1 protects cells from proteotoxic stresses by potentiating stress-induced HSF1 transcriptional activity.Crystal packing analysis of murine VDAC1 crystals in a lipidic environment reveals novel insights on oligomerization and orientation.Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development.Selective Induction of Cancer Cell Death by VDAC1-based Peptides and their Potential Use in Cancer Therapy.FV-429 induces apoptosis and inhibits glycolysis by inhibiting Akt-mediated phosphorylation of hexokinase II in MDA-MB-231 cells.
P2860
Q24651212-3EC3F415-5F74-4EE4-AC51-09A003DA8F0BQ26783189-3738780E-4117-41D7-8ABD-E9571166FED8Q27008995-45F65C7F-F967-48EF-AB7E-B53A4D04EAC5Q27652797-E9D6DCDB-11EC-4CC9-9DD6-7BECA9B0D1F3Q28658683-06F0B8C5-B07B-4283-96DA-513727EE6854Q30153379-C0736462-F790-404D-9AA0-79273ACA34AFQ33812904-BAE979A6-AB3E-4D4A-B7B2-AAC08B9EFE52Q33847153-C6F87F8F-CB36-4F8B-AE97-1E15675BF694Q33854939-EB2C69B3-339D-4BDA-84A7-EA69412220B7Q34010072-825A2DE6-F639-4525-A3E7-A5AE1177D556Q34117168-89B189FF-0DDD-489A-85C5-7848E14C1171Q34854255-3BD9BE96-0B86-4F37-8DE0-E2062F3522E6Q35679589-78915283-0F0C-4734-AF61-478F143828CFQ35831981-25ECAF98-6284-4446-8B4D-CCDB16789760Q36111593-5B336A4D-6AAE-4FD3-A905-FE6733750B85Q36137196-338DBF31-61EB-4C00-A065-C06A1ACA4C91Q36255034-FA7A7642-02F0-436E-BF1A-993BD404FE02Q36741184-061A3A19-49ED-4D32-A5EE-513CF51BE1EEQ36953477-0D704411-4E19-4104-B6E9-CCFE51EBF3C3Q37073594-D6872A48-182E-4D89-A72D-BD7E8A1AC429Q37079124-4AD7583C-A6C5-466B-9F72-5A89937D89FEQ37209189-DA0C08F6-53A0-4BA0-BC0F-0A3C3F686EB2Q37282524-75CF8BB0-A240-43D9-A94E-8CB8C0CC9546Q37714891-04C7CEDC-A6E2-4595-A3B6-039C39AB9AEDQ38040407-4C37223B-FBEB-4298-BD3F-A5EAA8522287Q38063744-8A966121-7778-4062-A6D6-450256D389C9Q38132274-E6222BEB-BCB4-4EF0-AA39-C6C7DBB33BEDQ38201407-9FB891A1-BC20-4FCA-9006-37D7903997C2Q38204222-69AFC17F-AA90-4A7D-8690-6AEA370F312FQ38255143-58EAC363-6E81-446B-A206-4EB63CC6B555Q39112253-042C7FA1-038C-4BD0-AE6B-31EA911B2B2AQ39224642-88143505-B6F0-4F1A-85A7-89DFF76E7A3EQ39609137-26ABCAE4-3416-467D-8B9D-AFACDAE5BD11Q39628723-BA57DDDF-544D-4004-A991-372C93883C5CQ39983817-686B6043-5BDA-4F03-929D-DD844726E107Q41241698-B93D0392-0CCE-418B-B858-B77334A1E06AQ42018123-39B8D7C0-BEFC-4A2C-8AE5-5BC93F7DB949Q50105551-545740E7-0FAC-4937-AD7A-18EEDF7160E3Q52561162-F21307A2-9CE7-4D05-B0E9-12ED8C4702C5Q53215395-E09466D9-76AA-4ACB-B67A-E266B307AFE7
P2860
Disruption of the hexokinase-VDAC complex for tumor therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Disruption of the hexokinase-VDAC complex for tumor therapy.
@en
Disruption of the hexokinase-VDAC complex for tumor therapy.
@nl
type
label
Disruption of the hexokinase-VDAC complex for tumor therapy.
@en
Disruption of the hexokinase-VDAC complex for tumor therapy.
@nl
prefLabel
Disruption of the hexokinase-VDAC complex for tumor therapy.
@en
Disruption of the hexokinase-VDAC complex for tumor therapy.
@nl
P2860
P50
P356
P1433
P1476
Disruption of the hexokinase-VDAC complex for tumor therapy.
@en
P2093
N Tajeddine
P2860
P2888
P304
P356
10.1038/ONC.2008.114
P407
P577
2008-05-12T00:00:00Z